Cargando…
Growth-Inhibiting Activity of Resveratrol Imine Analogs on Tumor Cells In Vitro
Although resveratrol exerts manifold antitumorigenic effects in vitro, its efficacy against malignancies in vivo seems limited. This has been increasingly recognized in recent years and has prompted scientists to search for structurally related compounds with more promising anticarcinogenic and/or p...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256997/ https://www.ncbi.nlm.nih.gov/pubmed/28114318 http://dx.doi.org/10.1371/journal.pone.0170502 |
_version_ | 1782498792112652288 |
---|---|
author | Wang, Shan Willenberg, Ina Krohn, Michael Hecker, Tanja Meckelmann, Sven Li, Chang Pan, Yuanjiang Schebb, Nils Helge Steinberg, Pablo Empl, Michael Telamon |
author_facet | Wang, Shan Willenberg, Ina Krohn, Michael Hecker, Tanja Meckelmann, Sven Li, Chang Pan, Yuanjiang Schebb, Nils Helge Steinberg, Pablo Empl, Michael Telamon |
author_sort | Wang, Shan |
collection | PubMed |
description | Although resveratrol exerts manifold antitumorigenic effects in vitro, its efficacy against malignancies in vivo seems limited. This has been increasingly recognized in recent years and has prompted scientists to search for structurally related compounds with more promising anticarcinogenic and/or pharmacokinetic properties. A class of structurally modified resveratrol derivatives, so-called resveratrol imine analogs (IRA’s), might meet these requirements. Therefore, the biological activity of five of these compounds was examined and compared to that of resveratrol. Firstly, the antiproliferative potency of all five IRA’s was investigated using the p53 wildtype-carrying colorectal carcinoma cell line HCT-116(wt). Then, using the former and a panel of various other tumor cell lines (including the p53 knockout variant HCT-116(p53-/-)), the growth-inhibiting and cell cycle-disturbing effects of the most potent IRA (IRA 5, 2-[[(2-hydroxyphenyl)methylene]amino]-phenol) were studied as was its influence on cyclooxygenase-2 expression and activity. Finally, rat liver microsomes were used to determine the metabolic stability of that compound. IRA 5 was clearly the most potent compound in HCT-116(wt) cells, with an unusually high IC(50)-value of 0.6 μM. However, in the other five cell lines used, the antiproliferative activity was mostly similar to resveratrol and the effects on the cell cycle were heterogeneous. Although all cell lines were affected by treatment with IRA 5, cells expressing functional p53 seemed to react more sensitively, suggesting that this protein plays a modulating role in the induction of IRA 5-mediated biological effects. Lastly, IRA 5 led to contradictory effects on cyclooxygenase-2 expression and activity and was less glucuronidated than resveratrol. As IRA 5 is approximately 50 times more toxic towards HCT-116(wt) cells, exerts different effects on the cyclooxygenase-2 and is metabolized to a lesser extent, it shows certain advantages over resveratrol and could therefore serve as basis for additional chemical modifications, potentially yielding compounds with more favorable biological and pharmacokinetic features. |
format | Online Article Text |
id | pubmed-5256997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-52569972017-02-06 Growth-Inhibiting Activity of Resveratrol Imine Analogs on Tumor Cells In Vitro Wang, Shan Willenberg, Ina Krohn, Michael Hecker, Tanja Meckelmann, Sven Li, Chang Pan, Yuanjiang Schebb, Nils Helge Steinberg, Pablo Empl, Michael Telamon PLoS One Research Article Although resveratrol exerts manifold antitumorigenic effects in vitro, its efficacy against malignancies in vivo seems limited. This has been increasingly recognized in recent years and has prompted scientists to search for structurally related compounds with more promising anticarcinogenic and/or pharmacokinetic properties. A class of structurally modified resveratrol derivatives, so-called resveratrol imine analogs (IRA’s), might meet these requirements. Therefore, the biological activity of five of these compounds was examined and compared to that of resveratrol. Firstly, the antiproliferative potency of all five IRA’s was investigated using the p53 wildtype-carrying colorectal carcinoma cell line HCT-116(wt). Then, using the former and a panel of various other tumor cell lines (including the p53 knockout variant HCT-116(p53-/-)), the growth-inhibiting and cell cycle-disturbing effects of the most potent IRA (IRA 5, 2-[[(2-hydroxyphenyl)methylene]amino]-phenol) were studied as was its influence on cyclooxygenase-2 expression and activity. Finally, rat liver microsomes were used to determine the metabolic stability of that compound. IRA 5 was clearly the most potent compound in HCT-116(wt) cells, with an unusually high IC(50)-value of 0.6 μM. However, in the other five cell lines used, the antiproliferative activity was mostly similar to resveratrol and the effects on the cell cycle were heterogeneous. Although all cell lines were affected by treatment with IRA 5, cells expressing functional p53 seemed to react more sensitively, suggesting that this protein plays a modulating role in the induction of IRA 5-mediated biological effects. Lastly, IRA 5 led to contradictory effects on cyclooxygenase-2 expression and activity and was less glucuronidated than resveratrol. As IRA 5 is approximately 50 times more toxic towards HCT-116(wt) cells, exerts different effects on the cyclooxygenase-2 and is metabolized to a lesser extent, it shows certain advantages over resveratrol and could therefore serve as basis for additional chemical modifications, potentially yielding compounds with more favorable biological and pharmacokinetic features. Public Library of Science 2017-01-23 /pmc/articles/PMC5256997/ /pubmed/28114318 http://dx.doi.org/10.1371/journal.pone.0170502 Text en © 2017 Wang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Wang, Shan Willenberg, Ina Krohn, Michael Hecker, Tanja Meckelmann, Sven Li, Chang Pan, Yuanjiang Schebb, Nils Helge Steinberg, Pablo Empl, Michael Telamon Growth-Inhibiting Activity of Resveratrol Imine Analogs on Tumor Cells In Vitro |
title | Growth-Inhibiting Activity of Resveratrol Imine Analogs on Tumor Cells In Vitro |
title_full | Growth-Inhibiting Activity of Resveratrol Imine Analogs on Tumor Cells In Vitro |
title_fullStr | Growth-Inhibiting Activity of Resveratrol Imine Analogs on Tumor Cells In Vitro |
title_full_unstemmed | Growth-Inhibiting Activity of Resveratrol Imine Analogs on Tumor Cells In Vitro |
title_short | Growth-Inhibiting Activity of Resveratrol Imine Analogs on Tumor Cells In Vitro |
title_sort | growth-inhibiting activity of resveratrol imine analogs on tumor cells in vitro |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256997/ https://www.ncbi.nlm.nih.gov/pubmed/28114318 http://dx.doi.org/10.1371/journal.pone.0170502 |
work_keys_str_mv | AT wangshan growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro AT willenbergina growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro AT krohnmichael growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro AT heckertanja growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro AT meckelmannsven growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro AT lichang growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro AT panyuanjiang growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro AT schebbnilshelge growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro AT steinbergpablo growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro AT emplmichaeltelamon growthinhibitingactivityofresveratrolimineanalogsontumorcellsinvitro |